DK0702560T3 - Immunforstærkning ved intermitterende interleukin-2 behandling - Google Patents

Immunforstærkning ved intermitterende interleukin-2 behandling

Info

Publication number
DK0702560T3
DK0702560T3 DK94920673T DK94920673T DK0702560T3 DK 0702560 T3 DK0702560 T3 DK 0702560T3 DK 94920673 T DK94920673 T DK 94920673T DK 94920673 T DK94920673 T DK 94920673T DK 0702560 T3 DK0702560 T3 DK 0702560T3
Authority
DK
Denmark
Prior art keywords
period
therapy
intermittent
treatment
infusions
Prior art date
Application number
DK94920673T
Other languages
Danish (da)
English (en)
Inventor
H Clifford Lane
Joseph A Kovacs
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0702560T3 publication Critical patent/DK0702560T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK94920673T 1993-05-19 1994-05-19 Immunforstærkning ved intermitterende interleukin-2 behandling DK0702560T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/063,315 US5419900A (en) 1993-05-19 1993-05-19 Immunologic enhancement with intermittent interleukin-2 therapy
PCT/US1994/005397 WO1994026293A1 (fr) 1993-05-19 1994-05-19 Facilitation immunologique par une therapie intermittente a l'interleukine-2

Publications (1)

Publication Number Publication Date
DK0702560T3 true DK0702560T3 (da) 2002-02-25

Family

ID=22048393

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94920673T DK0702560T3 (da) 1993-05-19 1994-05-19 Immunforstærkning ved intermitterende interleukin-2 behandling

Country Status (11)

Country Link
US (3) US5419900A (fr)
EP (1) EP0702560B1 (fr)
JP (1) JP4275193B2 (fr)
AT (1) ATE208206T1 (fr)
AU (1) AU691504B2 (fr)
CA (1) CA2163219A1 (fr)
DE (1) DE69428992T2 (fr)
DK (1) DK0702560T3 (fr)
ES (1) ES2167370T3 (fr)
PT (1) PT702560E (fr)
WO (1) WO1994026293A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696079A (en) * 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5419900A (en) * 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
EP0862651A2 (fr) * 1995-10-16 1998-09-09 Chiron Corporation Procede de criblage pour la recherche de facteurs qui modulent l'expression genique
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
CA2310805A1 (fr) * 1997-11-24 1999-06-03 Johnson T. Wong Procedes de traitement des infections par le vih ou autres infections utilisant un activateur de lymphocytes t ou un activateur viral et therapie d'association anti-retrovirale
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1141313A2 (fr) 1998-12-31 2001-10-10 Chiron Corporation Expression amelioree de polypeptides hiv et production de particules de type viral
PT1141315E (pt) * 1998-12-31 2008-05-05 Novartis Vaccines & Diagnostic Polipéptidos do envelope (env) de hiv modificados
US6921530B1 (en) * 1999-09-24 2005-07-26 Cornell Research Foundation, Inc. Low dose IL-2 for potentiation of immunity
FR2813793B1 (fr) * 2000-09-08 2003-01-24 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
WO2002020052A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
US6579521B2 (en) * 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
EP2280074A3 (fr) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
AU2002355955A1 (en) * 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
CA2458995C (fr) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
WO2005043155A1 (fr) 2003-10-21 2005-05-12 Cedars-Sinai Medical Center Systeme et methode pour le traitement du cancer, notamment des cancers du systeme nerveux central
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
WO2008039874A2 (fr) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Vaccins comprenant des antigènes de cellules souches cancéreuses et procédés
CA2700436C (fr) 2006-09-28 2017-04-18 John S. Yu Vaccins contre le cancer et methodes de vaccination
EP2328923B1 (fr) 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Épitopes cd133
ES2618573T3 (es) 2009-05-07 2017-06-21 ImmunoCellular Therapeutics,Ltd Epítopos de CD133
WO2011059836A2 (fr) 2009-10-29 2011-05-19 Trustees Of Dartmouth College Compositions de lymphocytes t déficientes en récepteurs de lymphocytes t
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2013033626A2 (fr) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Produits thérapeutiques ciblant un récepteur nkp30
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
WO2014127296A1 (fr) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Vaccins contre le cancer et méthodes de vaccination
JP6941561B2 (ja) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
US4863730A (en) 1986-03-21 1989-09-05 Cenfold Holdings, S.A. Immunotherapy for AIDS patients
US4868157A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4866157A (en) * 1987-11-10 1989-09-12 Sugio Otani Thermosetting aromatic resin composition
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
FR2653020B1 (fr) * 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DK0617124T3 (da) 1990-01-26 1999-12-06 Washington Res Found Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US5696079A (en) 1993-05-19 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy

Also Published As

Publication number Publication date
WO1994026293A1 (fr) 1994-11-24
EP0702560B1 (fr) 2001-11-07
JPH09500362A (ja) 1997-01-14
ES2167370T3 (es) 2002-05-16
JP4275193B2 (ja) 2009-06-10
PT702560E (pt) 2002-04-29
US6190656B1 (en) 2001-02-20
DE69428992T2 (de) 2002-08-14
DE69428992D1 (de) 2001-12-13
AU691504B2 (en) 1998-05-21
US6548055B1 (en) 2003-04-15
CA2163219A1 (fr) 1994-11-24
US5419900A (en) 1995-05-30
AU7137794A (en) 1994-12-12
EP0702560A1 (fr) 1996-03-27
ATE208206T1 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
DK0702560T3 (da) Immunforstærkning ved intermitterende interleukin-2 behandling
DK0504177T3 (da) IL-11, et pattedyrcytokin
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
MY103212A (en) Zinc-protamine-alpha interferon complex
DE69333580D1 (de) Immunregulation über die cd28-route
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
DK0911033T4 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
EP0177910A3 (fr) Application de préparations contenant de l'interféron-gamma (IFN-gamma) pour le traitement systématique de différentes maladies humaines à dose réduite
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
CA2063721A1 (fr) Medicament immunostimulant a base de glycopeptidolipides polaires de mycobacterium chelonae
RU94045248A (ru) Способ ингибирования активности вируса иммунодефицита человека (hiv) in vivo
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
Lane et al. Immunologic enhancement with intermittent interleukin-2 therapy
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
ES2110104T3 (es) Procedimiento para la administracion de soluciones de factor de estimulacion de las colonias de granulocitos.
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
Lein Immune-based therapies
RU95104171A (ru) Средство для лечения иммуносупрессии при сепсисе у человека и способ ее лечения
Grodeck IL-2 restores immune sytem
FR2427822A1 (fr) Medicament pour le traitement des maladies circulatoires, a base de 5-methyl-7-dimethylamino-s-triazolo (1,5-a) pyrimidine
Kurpisz et al. Blast transformation of lymphocytes induced by spermatozoa obtained from spermatocoele